Uniphyl and Eczema - a phase IV clinical study of FDA data

Summary:

Eczema is reported as a side effect among people who take Uniphyl (theophylline), especially for people who are male, 40-49 old, also take Spiriva, and have Asthma.

The phase IV clinical study analyzes which people have Eczema when taking Uniphyl. It is created by eHealthMe based on reports of 3,071 people who have side effects when taking Uniphyl from the FDA, and is updated regularly.

What is Uniphyl?

Uniphyl has active ingredients of theophylline. eHealthMe is studying from 3,086 Uniphyl users. Check the latest studies of Uniphyl.

What is Eczema?

Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters) is found to be associated with 1,484 drugs and 1,946 conditions by eHealthMe. Check the latest studies of Eczema.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Jul, 26, 2026

3,071 people reported to have side effects when taking Uniphyl.
Among them, 19 people (0.62%) have Eczema.

Among these 19 people:

What is the gender of people who have Eczema when taking Uniphyl? *

female: 42.11 %
male: 57.89 %

What is the age of people who have Eczema when taking Uniphyl? *

What are other drugs people take besides Uniphyl? *

What are other side effects people have besides Eczema? *

Weight Increased: 13 people, 68.42%
Nasopharyngitis (inflammation of the nasopharynx): 12 people, 63.16%
High Blood Pressure: 12 people, 63.16%
Sinusitis (inflammation of sinus): 12 people, 63.16%
Dyspnea (difficult or laboured breathing): 12 people, 63.16%
Itching: 11 people, 57.89%
Productive Cough: 11 people, 57.89%
Cough: 11 people, 57.89%
Sputum Discolored: 11 people, 57.89%
Weight Decreased: 11 people, 57.89%

What are the existing conditions these people have? *

Asthma: 16 people, 84.21%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 5.26%
Lung Cancer - Non-Small Cell (lung cancer): 1 person, 5.26%
Heavy Or Prolong Menstrual Bleeding: 1 person, 5.26%
Dyspnea (difficult or laboured breathing): 1 person, 5.26%
Diabetic Nephropathy (diabetic kidney disease): 1 person, 5.26%
Cough: 1 person, 5.26%
Birth Control: 1 person, 5.26%
Allergic Rhinitis: 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Uniphyl and have Eczema?

- Check whether Eczema is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Uniphyl:

Uniphyl (3,086 reports)

Eczema treatments and more:

Eczema (61,311 reports)

Browse all side effects of Uniphyl:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Eczema:

Eczema (1,484 drugs)

Browse all the conditions that are associated with Eczema:

Eczema (1,946 conditions)

Related publications that referenced our studies

Korang-Yeboah M, Rahman Z, Shah D, Mohammad A, Wu S, Siddiqui A, Khan MA, "Impact of formulation and process variables on solid-state stability of theophylline in controlled release formulations", International journal of pharmaceutics, 2016 Feb .
Dhaval MK, "Impact of formulation and process variables on solid-state stability of theophylline in controlled release formulations", International Journal of Pharmaceutics, 2016 Jan .
Korang-Yeboah M, Rahman Z, Shah D, Mohammad A, Wu S, Siddiqui A, Khan MA, "Impact of formulation and process variables on solid-state stability of theophylline in controlled release formulations", International journal of pharmaceutics, 2016 Feb .
Dhaval MK, "Impact of formulation and process variables on solid-state stability of theophylline in controlled release formulations", International Journal of Pharmaceutics, 2016 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on theophylline (the active ingredients of Uniphyl) and Uniphyl (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.